228 related articles for article (PubMed ID: 29641963)
1. Breakthrough-Therapy Designation - An FDA Perspective.
Corrigan-Curay J; McKee AE; Stein P
N Engl J Med; 2018 Apr; 378(15):1457-1458. PubMed ID: 29641963
[No Abstract] [Full Text] [Related]
2. The FDA Breakthrough-Drug Designation - Four Years of Experience.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
[No Abstract] [Full Text] [Related]
3. Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
[No Abstract] [Full Text] [Related]
4. New FDA breakthrough-drug category--implications for patients.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
[No Abstract] [Full Text] [Related]
5. Practical, legal, and ethical issues in expanded access to investigational drugs.
Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
[No Abstract] [Full Text] [Related]
6. Expediting drug development--the FDA's new "breakthrough therapy" designation.
Sherman RE; Li J; Shapley S; Robb M; Woodcock J
N Engl J Med; 2013 Nov; 369(20):1877-80. PubMed ID: 24224621
[TBL] [Abstract][Full Text] [Related]
7. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
[No Abstract] [Full Text] [Related]
8. FDA plans to continue cracking down on unapproved drugs.
Lavine G
Am J Health Syst Pharm; 2008 Sep; 65(17):1594. PubMed ID: 18714097
[No Abstract] [Full Text] [Related]
9. Drug development in serious diseases: the new "breakthrough therapy" designation.
Woodcock J
Clin Pharmacol Ther; 2014 May; 95(5):483-5. PubMed ID: 24747238
[TBL] [Abstract][Full Text] [Related]
10. 2013 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
[No Abstract] [Full Text] [Related]
11. Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany.
Daemmrich A; Krucken G
Sci Cult (Lond); 2000 Dec; 9(4):505-34. PubMed ID: 15988846
[No Abstract] [Full Text] [Related]
12. The Food and Drug Administration's experimental drug approval system: is it good for your health?
Myers BE
Houst Law Rev; 1991 Jan; 28(1):309-36. PubMed ID: 12426696
[No Abstract] [Full Text] [Related]
13. New FDA breakthrough-drug category--implications for patients.
Ricart AD
N Engl J Med; 2014 Jul; 371(1):89. PubMed ID: 24988580
[No Abstract] [Full Text] [Related]
14. New FDA breakthrough-drug category--implications for patients.
Velleca M
N Engl J Med; 2014 Jul; 371(1):88-9. PubMed ID: 24988579
[No Abstract] [Full Text] [Related]
15. New FDA breakthrough-drug category--implications for patients.
Murray BE
N Engl J Med; 2014 Jul; 371(1):88. PubMed ID: 24988578
[No Abstract] [Full Text] [Related]
16. New FDA breakthrough-drug category--implications for patients.
McClellan M; Sigal E
N Engl J Med; 2014 Jul; 371(1):87-8. PubMed ID: 24988577
[No Abstract] [Full Text] [Related]
17. New FDA breakthrough-drug category--implications for patients.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2014 Jul; 371(1):89-90. PubMed ID: 24988576
[No Abstract] [Full Text] [Related]
18. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
Khozin S; Liu K; Jarow JP; Pazdur R
Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
[No Abstract] [Full Text] [Related]
19. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.
Bateman-House A; Robertson CT
JAMA Intern Med; 2018 Mar; 178(3):321-322. PubMed ID: 29356821
[No Abstract] [Full Text] [Related]
20. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
Kwok M; Foster T; Steinberg M
Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
